Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), LymphomaNCT07782944
CD38 Targeted -PET/ CT for Multiple Myeloma
A study testing standard-of-care imaging (FDG PET/CT), CD38 PET/CT in people with Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, run by Guilin Medical University, China at 1 site in China.
Trial summary
The objective of the study is to construct a noninvasive approach CD38 targeted PET/CT to detect tumor lesions in patients with Multiple Myeloma and to compare with FDG PET/CT. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
- What is being tested?
- standard-of-care imaging (FDG PET/CT), CD38 PET/CT
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteChina
- Study dates
- 7 Jul 2026to 31 Dec 2030
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult patients (aged 18 years or older);
- Patients with newly diagnosed, highly suspected recurrence or previously treated metastases of Multiple Myeloma (supporting evidence may include MRI, CT, tumor markers, and pathology report);
- Patients who had scheduled both standard-of-care imaging (FDG PET/CT) and cd38 PET/CT scans;
- Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Who cannot join
- The inability or unwillingness of the research participant or legal representative to provide written informed consent.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Wei Fu contact
China1 site, 1 recruiting
- Recruiting
The First Affliated Hospital of Guilin Medical University
Guilin, Guangxi, 541001
Xingyu Mu, 86 13347631119, muxingyu1992@hotmail.com
About this study
Official title: Clinical Investigation of CD38-Targeted Molecular Imaging Probes in Multiple Myeloma
The objective of the study is to construct a noninvasive approach CD38 targeted PET/CT to detect tumor lesions in patients with Multiple Myeloma and to compare with FDG PET/CT.
Read the detailed description
CD38 targeting PET radiotracer is promising as an excellent imaging agent applicable to Multiple Myeloma. In this research, subjects with Multiple Myeloma or highly suspected recurrence detection underwent contemporaneous CD38 PET/CT and standard-of-care imaging (FDG PET/CT) either for an initial assessment or for metastases or highly suspected recurrence detection. Tumor uptake was quantified by the maximum standard uptake value (SUVmax). The numbers of positive tumor lesions of standard-of-care imaging and FDG PET/CT were recorded by visual interpretation. The diagnostic accuracy of CD38 PET/CT was calculated and compared to standard-of-care imaging.
- Being tested
- standard-of-care imaging (FDG PET/CT), CD38 PET/CT
- Keywords
- CD38, PET/CT, radiotracer, Multiple Myeloma
- Medical subject headings
- Multiple Myeloma, Lymphoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
standard-of-care imaging (FDG PET/CT), CD38 PET/CTDiagnostic test
Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceutical (FDG) and CD38, and undergoes PET/CT imaging within the specified time.
| Study group | Role | What they receive |
|---|---|---|
| CD38 PET/CT | Experimental | Each subject receives a single intravenous injection of radiolabeld CD38 and undergoes PET/CT imaging within the specified time. Receives: Diagnostic Test: standard-of-care imaging (FDG PET/CT), CD38 PET/CT |
What is being measured
The primary outcome is the main question the study is designed to answer.
Diagnostic efficacy
The sensitivity, specificity, and accuracy of standard-of-care imaging (FDG PET/CT) and CD38 PET/CT were calculated and compared to evaluate the diagnostic accuracy.
Measured: 3 year
Secondary outcomes (2)
Number of lesions
The numbers of positive primary and metastatic lesions of standard-of-care imaging (FDG PET/CT) and CD38 PET/CT were recorded by visual interpretation.
Measured: 3 year
SUV
Standardized uptake value (SUV) of standard-of-care imaging (FDG PET/CT) and CD38 PET/CT for each target lesion of subject or suspected primary tumor or/and metastasis.
Measured: 3 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Aug 2026
- Study start7 Jul 2026
- Primary completion31 Dec 2030 (estimated)
- Study completion31 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), LymphomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Guilin Medical University, China
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Wei Fu, Guilin Medical University, China
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07782944
- Sponsor's protocol ID
- 2025IITLL-10
- Status last verified
- Jul 2026
- First submitted
- 20 Aug 2026
- Last updated
- 24 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No